CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,812,468
- in 11 filings, $79.8M under 10b5-1 plans
Net −$79,812,468. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-15 | Baynes Roy D. Director | Grant or award | +6,500 | 37,500 | ||
| 2025-05-15 | Baynes Roy D. Director | Grant or award · Stock option (right to buy) | +19,500 | 19,500 | ||
| 2025-05-05 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale | −1,784 | $21.05 | $38K | 93,126 |
| 2025-05-05 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −18,924 | $21.05 | $398K | 419,173 |
| 2025-05-05 | Heerma Peter CHIEF COMMERCIAL OFFICER | Sale | −1,771 | $21.05 | $37K | 128,215 |
| 2025-05-05 | ROTE WILLIAM E. Chief Research Officer | Sale 10b5-1 | −3,198 | $21.05 | $67K | 100,241 |
| 2025-05-05 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −4,920 | $21.05 | $104K | 89,482 |
| 2025-05-02 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Option exercise | +4,920 | 94,910 | ||
| 2025-05-02 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Option exercise · Performance-based restricted stock units | −4,920 | 4,920 | ||
| 2025-05-02 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 | +18,924 | 438,097 | ||
| 2025-05-02 | Dube Eric M CHIEF EXECUTIVE OFFICER | Option exercise · Performance-based restricted stock units 10b5-1 | −18,924 | 18,924 | ||
| 2025-05-02 | Heerma Peter CHIEF COMMERCIAL OFFICER | Option exercise | +4,920 | 129,986 | ||
| 2025-05-02 | Heerma Peter CHIEF COMMERCIAL OFFICER | Option exercise · Performance-based restricted stock units | −4,920 | 4,920 | ||
| 2025-05-02 | ROTE WILLIAM E. Chief Research Officer | Option exercise 10b5-1 | +4,920 | 103,439 | ||
| 2025-05-02 | ROTE WILLIAM E. Chief Research Officer | Option exercise · Performance-based restricted stock units 10b5-1 | −4,920 | 4,920 | ||
| 2025-05-02 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise 10b5-1 | +4,920 | 94,402 | ||
| 2025-05-02 | REED ELIZABETH E Chief Legal Officer and GC | Option exercise · Performance-based restricted stock units 10b5-1 | −4,920 | 4,920 | ||
| 2025-04-11 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale | −48 | $13.14 | $631 | 89,990 |
| 2025-02-12 | ROTE WILLIAM E. SENIOR VICE PRESIDENT, R&D | Sale 10b5-1 | −5,200 | $23.53 | $122K | 98,519 |
| 2025-02-12 | REED ELIZABETH E SVP, GC & CORPORATE SECRETARY | Sale 10b5-1 | −8,000 | $23.53 | $188K | 89,482 |
Page 18 of 51 · 1,020 trades